您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Vanillylmandelic acid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vanillylmandelic acid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vanillylmandelic acid图片
包装:25mg
规格:98%
市场价:445元
分子量:198.17

产品介绍
Vanillylmandelicacid是肾上腺素和去甲肾上腺素代谢的最终产物。Vanillylmandelicacid也可作为神经递质代谢紊乱的标志物。Vanillylmandelicacid具有抗氧化(antioxidant)活性,清除DPPH自由基的IC50值为33μM。
货号:ajcx31774
CAS:55-10-7
分子式:C9H10O5
分子量:198.17
溶解度:DMSO: 250 mg/mL (1261.54 mM)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM[1].

Vanillylmandelic acid has antioxidant activity, the IC50 value is determined as the amount of VMA required to reduce 50% of the starting concentration of free radical is 33*10-6 M in the UV-Vis decolourisation DPPH assay[1].

Vanillylmandelic acid (intra-arterial injection over 1 min; 1, 10 and 100 mg/kg; the 60 min-observation period) produces a significant difference between vanillylmandelic acid groups and controls. Vanillylmandelic acid decreases the heart rate by 17.5%, 17.9% and 18.9% after 1, 10 and 100 mg/kg, respectively. Mean blood pressure is decreased by 13.5% in control animals as compared to 37%, 23% and 26% after 1, 10 and 100 mg/kg, respectively, in wistar rats[1].

[1]. Michalis K Kolentinis, et al.Cardiovascular effects of vanillylmandelic acid in rats. Eur J Pharmacol. 2013 Mar 5;703(1-3):46-52. [2]. Dušan Dimi?, et al. Experimental and theoretical elucidation of structural and antioxidant properties of vanillylmandelic acid and its carboxylate anion. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Jun 5;198:61-70.